Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) successfully completed the acquisition of Mersana Therapeutics, Inc. (NASDAQ: MRSN) at a price of $25 per share in cash.
The acquisition expands Day One's pipeline with a clinical-stage ADC targeting rare cancer adenoid cystic carcinoma (ACC) called Emi-Le.
Emi-Le represents a potentially transformative advancement in the treatment of ACC, filling an unmet medical need in the market.
Strategic Fit with Mission
The acquisition of Mersana aligns with Day One's mission and ambitions, allowing expansion into adult oncology while focusing on rare cancers.
Novel ADC Addition
The acquisition adds Emi-Le, a novel ADC directed against B7-H4, to Day One's clinical pipeline for targeting ACC.
Terms of Acquisition
Day One acquired all outstanding shares of Mersana at $25 per share in cash, with an additional non-tradable CVR per share for milestone payments, totaling up to $55.25 per share.
- The acquisition strengthens Day One's position in the market to deliver sustainable business growth and expand their impact on patient communities.
- Emi-Le, with promising early clinical data, represents a significant advancement in the treatment of adenoid cystic carcinoma (ACC), a challenging rare cancer.
Day One's acquisition of Mersana Therapeutics marks a strategic move to enhance their oncology pipeline and address unmet medical needs in rare cancers, positioning the company for continued growth and impactful contributions to patient care.